Dissecting spatiotemporal heterogeneity of glioblastoma evolution under therapy
Project Number5K99CA286730-02
Contact PI/Project LeaderMIGLIOZZI, SIMONA
Awardee OrganizationUNIVERSITY OF MIAMI SCHOOL OF MEDICINE
Description
Abstract Text
PROJECT SUMMARY:
Glioblastoma (GBM) is an uncurable form of primary brain tumor with extremely poor prognosis. Despite multi-
modal therapy including surgery, irradiation and chemotherapy, all patients experience tumor progression. No
standard of care is established in recurrent or progressive GBM. The identification of a neuronal cellular state of
GBM as a more differentiated state enriched at recurrence and periphery of the tumor provides new insights into
how neuronal activity regulates tumor invasion. Deconvolution of normal cell types from single-cell RNAseq and
bulk tumors revealed that neuronal state of GBM is associated with high infiltration of non-malignant cells. The
intricate synaptic communications between neurons and brain tumor cells are crucial for glioma progression and
resistance to standard therapies, which is supported by ample data from the rapidly emerging field of “cancer
neuroscience”. However, the molecular mechanisms driving enhanced neuronal activity at recurrence remains
to be understood. Dissecting the spatiotemporal dynamics of glioma eco-system during evolution will be
necessary to identify therapeutic vulnerability of recurrent GBM. Here, proteogenomics and single-nuclei
RNAseq profiling of matched primary and recurrent GBM IDH wild-type suggest that the evolutionary transition
from a more proliferative-progenitor towards the neuronal state in GBM is regulated by both genetic and post-
genetic molecular events and potential functional interactions between malignant and non-malignant cells. In
Aim 1, the development of a multiomics-based network diffusion approach will enlighten subnetworks of
proteins/phospho-proteins significantly affected by upstream genetic events driving activation of neuronal
programs during progression. Generation of in silico knock-out networks screen and integrative analysis of
proteomics and pharmacological data of cancer cell lines will prioritize lethal and essential proteins in the
subnetworks to identify potential therapeutic vulnerabilities in neuronal-recurrent GBM. In Aim 2, single-nuclei
and spatial transcriptomics profiling of matched primary and recurrent GBM IDH wild-type will identify the
functional connections between neurodevelopmental tumor cellular states and cell types in tumor
microenvironment. The development of a spatial informed cell–cell communications algorithm and the
reconstruction of intercellular signaling networks will infer the key functional interactions between
neurodevelopmental tumor cellular states and cell types in tumor microenvironment along with the potential effect
of these interactions on downstream regulatory molecular pathways. These studies lay the foundation for my
future research program and will advance the understanding of the molecular mechanisms mediating glioma
connectomes and driving glioma invasion. These studies will advance the neuroscience field through discovery
of targetable pathways and proteins providing therapeutic opportunities for recurrent GBM.
Public Health Relevance Statement
PROJECT NARRATIVE
Enhanced neuronal activity is a major mechanism facilitating the progression and therapeutic resistance of
glioblastoma (GBM), the most lethal form of primary brain tumor. The objective of this proposal is to enlighten
the molecular mechanisms driving the activation of the neuronal program at recurrence of GBM and to address
whether and how the tumor cells shape their microenvironment to support glioma invasion through integration of
multi-omics with protein interaction networks, prioritization of targetable proteins and integrative analysis of
spatial and single cell transcriptomics. The successful completion of this proposal will elucidate the key molecular
drivers prompting the increased neuronal activity at recurrence and the dynamics of the functional links between
malignant and non-malignant cells during the progression of GBM.
No Sub Projects information available for 5K99CA286730-02
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5K99CA286730-02
Patents
No Patents information available for 5K99CA286730-02
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5K99CA286730-02
Clinical Studies
No Clinical Studies information available for 5K99CA286730-02
News and More
Related News Releases
No news release information available for 5K99CA286730-02
History
No Historical information available for 5K99CA286730-02
Similar Projects
No Similar Projects information available for 5K99CA286730-02